电邮这篇文章 Clinical significance of the pathological type of tumor in common forms of ovarian cancer: A retrospective study
- 作者: Zhurman V.N.1,2
-
隶属关系:
- Primorsky Regional Oncological Dispensary
- Pacific State Medical University
- 期: 卷 25, 编号 2 (2023)
- 页面: 241-243
- 栏目: CLINICAL ONCOLOGY
- URL: https://bakhtiniada.ru/1815-1434/article/view/132824
- DOI: https://doi.org/10.26442/18151434.2023.2.202091
- ID: 132824
如何引用文章
全文:
详细
Background. Epithelial forms of ovarian cancer account for up to 90% of all ovarian malignancies. Epithelial forms of ovarian cancer are classified according to the WHO criteria of 2014 into several types: the most common are serous carcinomas (70%), mucinous carcinomas (3%), endometrioid tumors (10%), light cell cancer, transitional cell cancer, mixed and undifferentiated carcinomas are rare.
Aim. To study the overall survival and progression-free survival depending on the stage of the disease, the pathological type of tumor and the degree of differentiation of tumor cells.
Materials and methods. A retrospective analysis of the treatment of 467 patients with stage IIIC–IVB ovarian cancer in the Primorsky Regional Oncological Dispensary for the period from 2003 to 2021 was carried out. The obtained parameters were processed using standard statistical analysis methods using the IBM SPSS Statistics 26 program.
Results. The overall results showed that the most favorable course of stage IIIC–IVB ovarian cancer has a serous type of ovarian cancer, probably due to its sensitivity to chemotherapy and aggressive surgical tactics. Patients with a mutation in the BRCA1/2 genes have a better prognosis in overall survival rates. BRCA1/2 mutations are associated with an improved response to chemotherapy with platinum-based drugs.
Conclusion. The analysis made it possible to determine the most favorable prognostic factors for advanced stages of ovarian cancer, when comparing the groups of high-grade and low-grade III–IV stage serous carcinoma, it was noted that the median overall survival, depending on the histological type, is better in the group of patients with low-grade III–IV stage serous carcinoma. When comparing, depending on the timing of the operation performed, it can be noted that the median overall survival and median progression-free survival rates are better in the group of patients who received primary cytoreductive surgery.
作者简介
Varvara Zhurman
Primorsky Regional Oncological Dispensary; Pacific State Medical University
编辑信件的主要联系方式.
Email: varvara2007@yandex.ru
ORCID iD: 0000-0002-6927-3336
SPIN 代码: 1781-0007
Candidate of Medical Sciences, oncologist-gynecologist of the oncological gynecological department
俄罗斯联邦, st. Russkay 63A, 690000 Vladivostok; Vladivostok参考
- Солопова А.Е., Чащин А.А., Солопова А.Г., Макацария А.Д. Эпителиальный рак яичников. Клиническая лекция. Акушерство, гинекология и репродукция. 2016;10(3):53-65 [Solopova AE, Chaschin AA, Solopova AG, Makatsariya AD. Epithelial ovarian cancer. Clinical lecture. Obstetrics gynecology and Reproduction. 2016;10(3):53-65 (in Russian)]. doi: 10.17749/2313-7347.2016.10.2.053-065
- Wilkinson N. Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag, 2014.
- Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013;24(6):vi24-32.
- Gusehet SH, Rauh-Hain JA, Tambouret RH, et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecol Oncol. 2014;132:649-53.
- Kurman RJ. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J Surg Pathol. 2010;34(3):433-43.
- Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011;474(7353):609-15.
- Young RC, Pecorelly S. Management of early ovarian cancer. Sem Oncol. 1998;25:335.
- Omura GA, Brody MF, Homesley HD, et al. Long term follow up and prognostic factor analysis in advanced ovarian carcinomas: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138.
- Huang YW. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine. 2018;97(2):e9380. doi: 10.1097/MD.0000000000009380
- Тюляндина А.С., Коломиец Л.А., Морхов К.Ю., и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2021;11:10 [Tulyandina AS, Kolomiec LA, Morhov KU, et al. Practical recommendations for the drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Malignant tumors: Practical recommendations RUSSCO #3s2. 2021;11:10 (in Russian)]. doi: 10.18027/2224-5057-2021-11-3s2-10
- Коцюрбий Е.А., Тихонов Я.Н., Назарова И.В., и др. Практическое использование метода клеточных блоков для диагностики новообразований поджелудочной железы и опухолевых процессов других локализаций. Тихоокеанский медицинский журнал. 2020;(4):90-2 [Kotsyrbiy EA, Tychonov YN, Nazarova IV, et al. Practical application of the cell block technique for the diagnostics of the tumors of the pancreas and of other localizations. Pacific Medical Journal. 2020;(4):90-2 (in Russian)]. doi: 10.34215/1609-1175-2020-4-90-92.
补充文件
